MK-677 · Research brief

Can You Take MK-677 Orally? (Bioavailability & Dosing)

Real Peptides Research TeamEditorial

Updated April 10, 20269 min read

49 WORDS

Short answer

Key takeaways

MK-677 achieves 60–80% oral bioavailability because it's a non-peptide ghrelin mimetic without peptide bonds vulnerable to gastric degradation.
Clinical trials administered MK-677 exclusively as oral capsules at doses of 10–50mg daily for periods exceeding 12 months without requiring injection.
Taking MK-677 with food reduces peak plasma concentration by approximately 30% due to delayed gastric emptying and increased first-pass hepatic metabolism.
Liquid formulations in PEG-400 maintain potency for 6–8 months at room temperature; capsules extend shelf life to 18–24 months under identical storage conditions.
MK-677 produces sustained 24-hour GH elevation per dose, fundamentally different from the pulsatile pattern seen with injectable peptides like CJC-1295 or ipamorelin.
Proton pump inhibitors and H2 blockers can impair dissolution of certain MK-677 formulations by raising gastric pH above 4.0.

Most growth hormone secretagogues require subcutaneous injection because gastric acid destroys peptide bonds before absorption occurs. MK-677 (ibutamoren) is the exception. It's structured as a non-peptide ghrelin receptor agonist. A small molecule with a molecular weight of 528 Da that survives first-pass metabolism and achieves oral bioavailability between 60–80%. This isn't theoretical: Phase 2 trials published in the Journal of Clinical Endocrinology & Metabolism administered MK-677 exclusively as oral capsules at doses ranging from 10–50mg daily for periods exceeding 12 months without requiring injection at any stage.

We've worked with research teams using both peptide-based secretagogues and MK-677 in parallel protocols. The preparation difference is night and day. No reconstitution, no refrigerated storage, no injection site rotation logs.

Can you take MK-677 orally and achieve the same GH pulse elevation as injectable peptides?

Yes, you take MK-677 orally as a capsule or liquid solution. Unlike true peptides such as CJC-1295 or ipamorelin, MK-677 bypasses gastric degradation because it lacks peptide bonds vulnerable to pepsin cleavage. Oral administration produces sustained growth hormone elevation for 24 hours per dose with peak plasma concentration occurring 2–3 hours post-ingestion. Clinical trials demonstrate 60–80% bioavailability via oral route. No injection required.

MK-677 oral dosing removes three variables that complicate peptide research: reconstitution errors, injection timing precision, and cold-chain storage failures. The compound arrives as a pre-formulated capsule or liquid suspension, remains stable at room temperature for extended periods, and delivers consistent plasma levels without the sharp peak-and-trough pattern seen with injectable growth hormone secretagogues. This piece covers the exact mechanism that allows oral absorption, proper dosing protocols for research applications, and what preparation mistakes eliminate the bioavailability advantage entirely.

Why MK-677 Survives Oral Administration

Most peptides fragment in the stomach. Pepsin. The primary gastric protease. Cleaves peptide bonds at aromatic amino acid residues, breaking down compounds like sermorelin or hexarelin before they reach the intestinal mucosa. MK-677 sidesteps this entirely because it's not a peptide. It's a spiropiperidine structure, classified chemically as a growth hormone secretagogue receptor (GHSR) agonist. No peptide bonds exist to cleave.

The compound binds to ghrelin receptors in the anterior pituitary with an affinity comparable to endogenous ghrelin itself (Ki = 0.4 nM), triggering the same downstream cascade: GH release via Gαq/11 signaling and calcium mobilization. But unlike ghrelin. A 28-amino-acid peptide with a half-life measured in minutes. MK-677 has a plasma half-life of approximately 4–6 hours and remains orally active across multiple doses per day.

Oral bioavailability studies show 60–80% absorption when taken on an empty stomach. Food co-administration reduces this to approximately 50% due to delayed gastric emptying and increased first-pass hepatic metabolism. Research protocols typically specify morning dosing 30–60 minutes before the first meal to maximize plasma concentration. The practical implication: you take MK-677 orally without injection, but timing relative to food intake matters more than most researchers initially assume.

Dosing Precision and Plasma Stability

MK-677 dosing in clinical trials ranged from 10mg to 50mg daily, with 25mg emerging as the most common therapeutic dose for sustained GH elevation without dose-limiting side effects. Unlike pulsatile peptides that require precise injection timing to align with natural secretory patterns, MK-677 produces sustained elevation across the entire dosing interval. A single 25mg oral dose elevates serum IGF-1 by 60–80% within 14 days of daily administration and maintains that elevation for the duration of the protocol.

The mechanism differs fundamentally from exogenous GH or GHRH analogs. MK-677 amplifies endogenous pulsatility rather than replacing it. Meaning natural circadian GH secretion patterns remain intact. Sleep-associated GH pulses still occur; they're simply higher-amplitude. This preserved physiological rhythm is one reason MK-677 demonstrates a more favorable side effect profile in long-term studies compared to continuous GH infusion.

Liquid formulations allow dose titration in 5mg increments, which matters for protocols exploring dose-response relationships. Capsules offer superior shelf stability and eliminate measurement error but restrict flexibility. Our team has found that liquid suspensions in polyethylene glycol (PEG-400) maintain potency for 6–8 months at room temperature when stored in amber glass bottles away from direct light. Capsules extend this to 18–24 months under identical conditions.

What Reduces MK-677 Oral Bioavailability

Three variables consistently reduce absorption: food co-administration, gastric pH elevation, and formulation degradation. Taking MK-677 with a high-fat meal delays gastric emptying by 60–90 minutes and reduces peak plasma concentration by approximately 30%. The compound isn't destroyed. It's absorbed more slowly and incompletely as hepatic first-pass metabolism increases during prolonged intestinal transit time.

Proton pump inhibitors (PPIs) and H2 receptor antagonists raise gastric pH above 4.0, which impairs MK-677 dissolution in some formulations. The compound itself is stable across pH ranges, but certain excipients require acidic conditions for proper release. Enteric-coated capsules bypass this issue entirely but add cost. Standard gelatin capsules work fine at physiological gastric pH (1.5–3.5) but may underperform in individuals on chronic PPI therapy.

Formulation degradation occurs when liquid suspensions are stored above 25°C for extended periods or exposed to repeated freeze-thaw cycles. MK-677 itself is thermally stable, but carrier solvents like PEG can oxidize over time, forming peroxides that degrade the active compound. Capsules eliminate this vector entirely, which is why MK 677 from verified suppliers typically ships in capsule form for research applications requiring multi-month stability.

Can You Take MK-677 Orally: Research Applications Comparison

Administration Route	Bioavailability	Dosing Frequency	Storage Requirements	Measurement Precision	Typical Research Use Case
Oral capsule (MK-677)	60–80% fasted	Once daily	Room temperature, amber bottle	±2mg (capsule weight variation)	Long-term GH elevation studies, metabolic research
Oral liquid (MK-677)	60–80% fasted, 50% fed	Once daily	Room temp or 2–8°C depending on formulation	±0.5mg with calibrated syringe	Dose titration studies, pharmacokinetic profiling
Subcutaneous injection (CJC-1295)	~100%	1–2× weekly	2–8°C refrigeration required	±5 mcg with insulin syringe	Pulsatile GH studies, circadian rhythm research
Subcutaneous injection (Ipamorelin)	~100%	2–3× daily	2–8°C refrigeration required	±5 mcg with insulin syringe	Acute GH pulse research, receptor saturation studies

What If: MK-677 Oral Dosing Scenarios

What If You Take MK-677 With a Meal Instead of Fasted?

Administer the next dose on an empty stomach and continue the regular schedule. Bioavailability drops to approximately 50% when taken with food, but the compound still absorbs. It's delayed, not destroyed. Peak plasma concentration shifts from 2–3 hours to 4–6 hours post-dose, and total AUC (area under the curve) decreases by roughly 30%. For single-dose pharmacokinetic studies, this creates a confounding variable. For long-term protocols where steady-state plasma levels matter more than individual peaks, one fed dose out of 90 consecutive fasted doses has minimal impact on cumulative IGF-1 elevation.

What If the Liquid Formulation Turns Cloudy or Changes Color?

Discard it immediately. Cloudiness in a previously clear PEG-400 suspension indicates either microbial contamination or excipient oxidation. Both compromise compound integrity. MK-677 itself is a white to off-white powder; any yellow, brown, or orange discoloration in the solution suggests degradation byproducts. This typically occurs after 8–12 months at room temperature or following temperature excursions above 30°C. Capsules don't exhibit visible degradation markers, which is one reason they're preferred for protocols extending beyond six months. Always verify supplier CoA (certificate of analysis) includes HPLC purity data and endotoxin testing.

What If You Miss a Scheduled Oral Dose by 12+ Hours?

Take the missed dose as soon as remembered if fewer than 18 hours have passed since the scheduled time, then resume the regular daily schedule. If more than 18 hours have elapsed, skip the missed dose entirely and continue with the next scheduled dose. Do not double-dose to compensate. MK-677 has a plasma half-life of 4–6 hours, meaning a single missed dose drops plasma concentration below threshold within 24 hours, but doubling the dose produces supraphysiological GH spikes (300–400% baseline) that increase the risk of transient insulin resistance and fluid retention. Consistency matters more than compensation.

What If You're Running a Protocol That Requires Dose Escalation?

Start at 10mg daily for the first week to assess individual tolerance, then increase to 25mg daily for the maintenance phase. Dose escalation reduces the incidence of transient water retention and mild insulin resistance. The two most common side effects reported in clinical trials. These effects are dose-dependent and typically resolve within 2–3 weeks as the body adapts to elevated GH and IGF-1 levels. Liquid formulations allow 5mg titration increments; capsules require purchasing multiple strengths or using a capsule cutter (which works but introduces minor dose variability). Research protocols exploring dose-response relationships above 25mg daily should monitor fasting glucose and HbA1c at baseline and monthly intervals.

The Unvarnished Truth About MK-677 Oral Efficacy

Here's the honest answer: MK-677 works orally because it's not competing in the same category as true peptides. The marketing conflates it with compounds like CJC1295 Ipamorelin 5MG 5MG, but the mechanisms are completely different. Peptides require injection because gastric acid destroys them. MK-677 doesn't have that vulnerability. It's a small-molecule drug that happens to target the same receptor system.

The oral route isn't a compromise. It's the intended administration method. Every Phase 2 and Phase 3 trial used oral dosing. No researcher ever injected MK-677 subcutaneously in a published study because there's no pharmacological reason to bypass the GI tract. The compound survives it just fine.

What this means for research design: if your protocol involves daily dosing over weeks or months, MK-677 eliminates injection compliance issues, cold-chain logistics, and reconstitution errors entirely. If you need acute GH pulses timed to specific intervals (sleep onset, exercise, feeding), injectable peptides remain the better tool. MK-677 produces sustained elevation. Not pulsatility. Choose the tool that matches the research question.

How Small-Molecule Structure Enables Oral Delivery

MK-677 contains a spiropiperidine core linked to a benzamide moiety through a sulfonamide bridge. This structure confers three properties critical for oral bioavailability: resistance to peptidase cleavage, sufficient lipophilicity to cross intestinal membranes, and stability across pH ranges from 1.5 (gastric) to 7.4 (plasma). The molecular weight of 528 Da sits well below Lipinski's Rule of Five threshold (500 Da) for drug-like oral compounds, and the calculated logP of 2.1 indicates balanced hydrophilic-lipophilic character.

Intestinal absorption occurs primarily in the duodenum and proximal jejunum via passive transcellular diffusion. MK-677 doesn't require active transport proteins, which is why genetic polymorphisms in drug transporters (e.g., P-glycoprotein, OATP1B1) don't meaningfully affect bioavailability the way they do for compounds like metformin or statins. First-pass hepatic metabolism does reduce systemic exposure. Hepatic extraction ratio is approximately 20–30%. But the parent compound and its primary metabolite (N-dealkylated MK-677) both retain ghrelin receptor agonist activity.

Compare this to Hexarelin, a six-amino-acid peptide with identical receptor target but zero oral bioavailability. Pepsin cleaves the His-D-Trp bond within minutes of gastric exposure. MK-677 has no such vulnerability because it contains no peptide bonds. This structural distinction is why you take MK-677 orally and inject hexarelin. The pharmacology dictates the route, not researcher preference.

Yes, you take MK-677 orally. And the reason has nothing to do with convenience. The compound's non-peptide structure allows it to survive gastric transit and achieve meaningful plasma concentrations without injection. For research applications requiring sustained GH elevation over weeks or months, this eliminates the compliance and logistics barriers that plague injectable peptide protocols. The tradeoff: you lose the acute pulsatility control that injected secretagogues provide. If your research question requires timing GH release to specific physiological windows, injectable peptides remain the better tool. If sustained elevation across the dosing interval is the goal, MK-677 oral administration delivers that outcome with fewer moving parts.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes, MK-677 is designed exclusively for oral administration and is never injected. Unlike true peptides that require injection to avoid gastric degradation, MK-677 is a non-peptide small molecule that survives stomach acid and achieves 60–80% bioavailability when taken as a capsule or liquid on an empty stomach. Every published clinical trial administered MK-677 orally — injection offers no pharmacological advantage and is not part of any standard research protocol.

MK-677 produces sustained 24-hour GH elevation from a single daily oral dose, while injectable peptides like ipamorelin or CJC-1295 create sharp pulses that mimic natural secretory patterns. Both routes elevate serum IGF-1, but the kinetics differ: oral MK-677 maintains steady plasma levels with a 4–6 hour half-life, whereas subcutaneous peptides peak within 30–60 minutes and clear within 2–4 hours. Research applications requiring sustained elevation favor oral MK-677; studies examining acute GH pulse dynamics require injection.

Clinical trials used oral doses ranging from 10mg to 50mg daily, with 25mg emerging as the most common dose for sustained IGF-1 elevation without significant side effects. Protocols typically start at 10mg daily for the first week to assess tolerance, then increase to 25mg for the maintenance phase. Doses above 25mg increase the incidence of transient water retention and mild insulin resistance without proportional increases in GH secretion. Liquid formulations allow 5mg titration increments; capsules require purchasing multiple strengths.

Yes, taking MK-677 with food reduces peak plasma concentration by approximately 30% and delays absorption from 2–3 hours to 4–6 hours post-dose. Bioavailability drops from 60–80% fasted to roughly 50% when taken with meals, particularly high-fat meals that slow gastric emptying. Research protocols specify dosing 30–60 minutes before the first meal to maximize absorption. One fed dose in a multi-week protocol has minimal impact on cumulative IGF-1 elevation, but consistent fed dosing reduces overall efficacy measurably.

Capsule formulations of MK-677 maintain potency for 18–24 months when stored at room temperature in amber bottles away from direct light and humidity. Liquid suspensions in PEG-400 remain stable for 6–8 months under the same conditions but degrade faster if exposed to temperatures above 25°C or repeated freeze-thaw cycles. Cloudiness or discoloration in liquid formulations indicates degradation — discard immediately. MK-677 does not require refrigeration like reconstituted peptides, but cool, dark storage extends shelf life for both formulations.

Splitting capsules introduces dose variability of ±15–20% due to uneven powder distribution and loss during opening. For protocols requiring precise titration, liquid formulations measured with a calibrated 1mL syringe offer ±0.5mg accuracy. If capsules are the only available form and dose adjustment is necessary, a capsule cutter produces more consistent splits than manual opening, but purchasing pre-dosed strengths (10mg, 15mg, 25mg) eliminates the issue entirely. Research applications with strict dosimetry requirements should avoid split capsules.

A single accidental double dose (50mg instead of 25mg) produces supraphysiological GH elevation (300–400% baseline) for 8–12 hours but typically resolves without intervention. Transient side effects include increased water retention, mild lethargy, and temporary insulin resistance measurable as elevated fasting glucose. Do not attempt to ‘skip’ the next scheduled dose to compensate — resume the regular daily schedule. Repeated double-dosing increases risk of persistent edema and impaired glucose tolerance. If symptoms persist beyond 24 hours, discontinue use and consult protocol supervisor.

No, oral bioavailability remains stable across continuous daily dosing for at least 12 months based on published pharmacokinetic data. Unlike some orally administered compounds that induce hepatic enzymes over time (reducing their own bioavailability), MK-677 does not significantly upregulate CYP450 metabolism. Serum IGF-1 levels plateau within 14–21 days of daily dosing and remain elevated at that plateau for the duration of administration. The lack of bioavailability drift is one reason MK-677 demonstrates consistent efficacy in long-term metabolic studies.

Proton pump inhibitors (PPIs) that raise gastric pH above 4.0 can impair dissolution of certain MK-677 formulations, particularly those using pH-sensitive excipients. The active compound itself is stable across pH ranges, but some capsule coatings require acidic conditions for proper release. Enteric-coated formulations bypass this issue entirely. For individuals on chronic PPI therapy, switching to an enteric-coated MK-677 capsule or liquid suspension eliminates the interaction. Standard gelatin capsules work reliably at physiological gastric pH (1.5–3.5) in individuals not taking acid-suppressing medications.

MK-677 is taken orally because it’s not a peptide — it’s a small-molecule ghrelin receptor agonist without peptide bonds vulnerable to gastric degradation. True peptides like sermorelin or ipamorelin are cleaved by pepsin in the stomach within minutes, which is why they must be injected to reach systemic circulation. MK-677’s spiropiperidine structure survives gastric acid, crosses intestinal membranes via passive diffusion, and achieves therapeutic plasma levels without injection. The oral route is the intended administration method, not a convenience adaptation.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA